Advertisement
News
Advertisement

Matakina and PenRad Sign Letter of Intent to Display Volparaâ„¢ Volumetric Breast Density Results on Mammography Review Station

Tue, 03/15/2011 - 5:32am
Bio-Medicine.Org

LAS VEGAS, March 15, 2011 /PRNewswire/ -- Matakina International, Limited of New Zealand and PenRad Technologies, Inc., a leader in medical image and information management, today announced that the companies have signed a Letter of Intent (LOI) to use the PenRad Mammography Information System (MIS) to display the Volpara™ breast imaging software. The announcement was made from the National Consortium of Breast Center's (NCBC) 21st Annual National Interdisciplinary Breast Center Conference.

Offering radiologists a reliable and cost-effective tool to automatically generate objective volumetric breast density values, the FDA-cleared Volpara breast imaging software computes volumetric breast tissue density from digital screening mammograms.  Volpara software assists radiologists by providing objective, automatic and robust measurement of volumetric breast tissue density and is currently available for Hologic and GE digital mammography systems with validation of integration with other systems underway.

Breast tissue density has not only been linked to an increased risk of breast cancer, it also decreases the sensitivity of the mammogram and thereby may impact early detection.  Several large studies have confirmed that as tissue density increases the accuracy of mammography decreases. Thirty-five percent of breast cancer goes undetected by mammography in women with dense breasts, as density masks the appearance of tumors (Boyd et al 2007, NEJM).  Since both dense breast tissue and cancer appear white on a mammogram, finding cancers can be analogous to looking for a snowball in a snow storm.

"PenRad shares our commitment to improving the detection of cancer through better access to critical breast health information," said Dr. Ralph Highnam, CEO, Matakina International, Ltd.  "The objective measurement of breast density clearly offers important clinical information, but the technology will not be used effectively

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading